drugset
drugset / Trial / NCT05707403

A Study in Healthy Men to Test How BI 1015550 is Taken up and Handled by the Body

NCT05707403 ↗

Phase 1 Completed 8 enrolled Boehringer Ingelheim
NaSingle-groupOpen-labelTreatment

Summary

This trial is intended to examine the absolute oral bioavailability of BI 1015550 as tablet formulation for oral administration, using an intravenous microtracer approach with \[14C\]-labelled BI 1015550. These data are considered necessary to further support the understanding of the pharmacokinetics of BI 1015550.

Timeline

Start
2023-02-14
Primary completion
2023-03-28
Completion
2023-03-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Nerandomilast Small molecule — Oral

Indications

No indication recorded.